{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:13:45Z","timestamp":1790691225518,"version":"4.1.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/nrgastro.2017.162","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T11:16:48Z","timestamp":1513163808000},"page":"235-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends"],"prefix":"10.1038","volume":"15","author":[{"given":"Peter S. N.","family":"van Rossum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Haj","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank P.","family":"Vleggaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"van Hillegersberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,13]]},"reference":[{"key":"BFnrgastro2017162_CR1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J.  et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359\u2013E386 (2015).","journal-title":"Int. J. Cancer"},{"key":"BFnrgastro2017162_CR2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur, A., Gibson, M. K., Jobe, B. A. & Luketich, J. D. Oesophageal carcinoma. Lancet 381, 400\u2013412 (2013).","journal-title":"Lancet"},{"key":"BFnrgastro2017162_CR3","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/gutjnl-2012-302412","volume":"62","author":"G Edgren","year":"2013","unstructured":"Edgren, G., Adami, H. O., Weiderpass, E. & Nyren, O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 62, 1406\u20131414 (2013).","journal-title":"Gut"},{"key":"BFnrgastro2017162_CR4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3748\/wjg.v17.i2.144","volume":"17","author":"G Diamantis","year":"2011","unstructured":"Diamantis, G.  et al. Quality of life in patients with esophageal stenting for the palliation of malignant dysphagia. World J. Gastroenterol. 17, 144\u2013150 (2011).","journal-title":"World J. Gastroenterol."},{"key":"BFnrgastro2017162_CR5","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(13)70136-0","volume":"14","author":"T Crosby","year":"2013","unstructured":"Crosby, T.  et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2\/3 randomised trial. Lancet Oncol. 14, 627\u2013637 (2013).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.11029","volume":"105","author":"AP Polednak","year":"2003","unstructured":"Polednak, A. P. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int. J. Cancer 105, 98\u2013100 (2003).","journal-title":"Int. J. Cancer"},{"key":"BFnrgastro2017162_CR7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.suc.2005.02.001","volume":"85","author":"NA Christie","year":"2005","unstructured":"Christie, N. A., Patel, A. N. & Landreneau, R. J. Esophageal palliation \u2014 photodynamic therapy\/stents\/brachytherapy. Surg. Clin. North Am. 85, 569\u2013582 (2005).","journal-title":"Surg. Clin. North Am."},{"key":"BFnrgastro2017162_CR8","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic, A.  et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N. Engl. J. Med. 326, 1593\u20131598 (1992).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2017162_CR9","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","volume":"281","author":"JS Cooper","year":"1999","unstructured":"Cooper, J. S.  et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85\u201301). JAMA 281, 1623\u20131627 (1999).","journal-title":"JAMA"},{"key":"BFnrgastro2017162_CR10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.radonc.2007.03.013","volume":"83","author":"S Kumar","year":"2007","unstructured":"Kumar, S.  et al. A randomised trial of radiotherapy compared with cisplatin chemo-radiotherapy in patients with unresectable squamous cell cancer of the esophagus. Radiother. Oncol. 83, 139\u2013147 (2007).","journal-title":"Radiother. Oncol."},{"key":"BFnrgastro2017162_CR11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clon.2010.12.001","volume":"23","author":"S Gwynne","year":"2011","unstructured":"Gwynne, S.  et al. Definitive chemoradiation for oesophageal cancer \u2014 a standard of care in patients with non-metastatic oesophageal cancer. Clin. Oncol. (R. Coll. Radiol.) 23, 182\u2013188 (2011).","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"BFnrgastro2017162_CR12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/dote.12215","volume":"28","author":"E Versteijne","year":"2015","unstructured":"Versteijne, E.  et al. Definitive chemoradiation for patients with inoperable and\/or unresectable esophageal cancer: locoregional recurrence pattern. Dis. Esophagus 28, 453\u2013459 (2015).","journal-title":"Dis. Esophagus"},{"key":"BFnrgastro2017162_CR13","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/1097-0142(19910501)67:9<2258::AID-CNCR2820670908>3.0.CO;2-G","volume":"67","author":"CM Araujo","year":"1991","unstructured":"Araujo, C. M.  et al. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 67, 2258\u20132261 (1991).","journal-title":"Cancer"},{"key":"BFnrgastro2017162_CR14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ncponc0796","volume":"4","author":"L Kleinberg","year":"2007","unstructured":"Kleinberg, L., Gibson, M. K. & Forastiere, A. A. Chemoradiotherapy for localized esophageal cancer: regimen selection and molecular mechanisms of radiosensitization. Nat. Clin. Pract. Oncol. 4, 282\u2013294 (2007).","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"Suppl. 3","key":"BFnrgastro2017162_CR15","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1245\/s10434-015-4840-5","volume":"22","author":"K Parry","year":"2015","unstructured":"Parry, K.  et al. Prognosis and treatment after diagnosis of recurrent esophageal carcinoma following esophagectomy with curative intent. Ann. Surg. Oncol. 22 (Suppl. 3), 1292\u20131300 (2015).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrgastro2017162_CR16","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1245\/s10434-013-2936-3","volume":"20","author":"RL Blom","year":"2013","unstructured":"Blom, R. L.  et al. Survival after recurrent esophageal carcinoma has not improved over the past 18 years. Ann. Surg. Oncol. 20, 2693\u20132698 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrgastro2017162_CR17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.semradonc.2012.09.003","volume":"23","author":"GY Ku","year":"2013","unstructured":"Ku, G. Y. & Ilson, D. H. Chemotherapeutic options for gastroesophageal junction tumors. Semin. Radiat. Oncol. 23, 24\u201330 (2013).","journal-title":"Semin. Radiat. Oncol."},{"key":"BFnrgastro2017162_CR18","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1016\/j.ejca.2013.07.003","volume":"49","author":"JA Ajani","year":"2013","unstructured":"Ajani, J. A.  et al. Combination of cisplatin\/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin\/5-fluorouracil in the first-line advanced gastric cancer study. Eur. J. Cancer 49, 3616\u20133624 (2013).","journal-title":"Eur. J. Cancer"},{"key":"BFnrgastro2017162_CR19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","volume":"14","author":"T Waddell","year":"2013","unstructured":"Waddell, T.  et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 481\u2013489 (2013).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR20","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S1470-2045(14)70024-5","volume":"15","author":"SJ Dutton","year":"2014","unstructured":"Dutton, S. J.  et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 15, 894\u2013904 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HE Ford","year":"2014","unstructured":"Ford, H. E.  et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 15, 78\u201386 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs, C. S.  et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31\u201339 (2014).","journal-title":"Lancet"},{"key":"BFnrgastro2017162_CR23","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1200\/JCO.2013.54.1011","volume":"32","author":"R Guimbaud","year":"2014","unstructured":"Guimbaud, R.  et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J. Clin. Oncol. 32, 3520\u20133526 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR24","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke, H.  et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224\u20131235 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","volume":"34","author":"JR Hecht","year":"2016","unstructured":"Hecht, J. R.  et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC \u2014 a randomized phase III trial. J. Clin. Oncol. 34, 443\u2013451 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.6004\/jnccn.2015.0028","volume":"13","author":"JA Ajani","year":"2015","unstructured":"Ajani, J. A.  et al. Esophageal and esophagogastric junction cancers, version 1.2015. J. Natl Compr. Canc. Netw. 13, 194\u2013227 (2015).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"BFnrgastro2017162_CR27","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1136\/gut.2010.228254","volume":"60","author":"WH Allum","year":"2011","unstructured":"Allum, W. H.  et al. Guidelines for the management of oesophageal and gastric cancer. Gut 60, 1449\u20131472 (2011).","journal-title":"Gut"},{"key":"BFnrgastro2017162_CR28","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.ejso.2013.12.024","volume":"40","author":"M Koeter","year":"2014","unstructured":"Koeter, M.  et al. Hospital of diagnosis and probability to receive a curative treatment for oesophageal cancer. Eur. J. Surg. Oncol. 40, 1338\u20131345 (2014).","journal-title":"Eur. J. Surg. Oncol."},{"key":"BFnrgastro2017162_CR29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2010.03.002","volume":"78","author":"KK Cheng","year":"2011","unstructured":"Cheng, K. K. & Lee, D. T. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit. Rev. Oncol. Hematol. 78, 127\u2013137 (2011).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"BFnrgastro2017162_CR30","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s00520-014-2311-3","volume":"22","author":"MA Silvers","year":"2014","unstructured":"Silvers, M. A., Savva, J., Huggins, C. E., Truby, H. & Haines, T. Potential benefits of early nutritional intervention in adults with upper gastrointestinal cancer: a pilot randomised trial. Support. Care Cancer 22, 3035\u20133044 (2014).","journal-title":"Support. Care Cancer"},{"key":"BFnrgastro2017162_CR31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11894-012-0272-6","volume":"14","author":"KR Miller","year":"2012","unstructured":"Miller, K. R. & Bozeman, M. C. Nutrition therapy issues in esophageal cancer. Curr. Gastroenterol. Rep. 14, 356\u2013366 (2012).","journal-title":"Curr. Gastroenterol. Rep."},{"issue":"Suppl. 2","key":"BFnrgastro2017162_CR32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00520-009-0664-9","volume":"18","author":"F Bozzetti","year":"2010","unstructured":"Bozzetti, F. Nutritional support in patients with oesophageal cancer. Support. Care Cancer 18 (Suppl. 2), 41\u201350 (2010).","journal-title":"Support. Care Cancer"},{"key":"BFnrgastro2017162_CR33","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1111\/j.1572-0241.2007.01437.x","volume":"102","author":"F Di Fiore","year":"2007","unstructured":"Di Fiore, F.  et al. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am. J. Gastroenterol. 102, 2557\u20132563 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2017162_CR34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.clon.2005.03.015","volume":"17","author":"C Odelli","year":"2005","unstructured":"Odelli, C.  et al. Nutrition support improves patient outcomes, treatment tolerance and admission characteristics in oesophageal cancer. Clin. Oncol. (R. Coll. Radiol.) 17, 639\u2013645 (2005).","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"BFnrgastro2017162_CR35","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.ejca.2006.05.028","volume":"42","author":"C Baldwin","year":"2006","unstructured":"Baldwin, C.  et al. Failure of dietetic referral in patients with gastrointestinal cancer and weight loss. Eur. J. Cancer 42, 2504\u20132509 (2006).","journal-title":"Eur. J. Cancer"},{"key":"BFnrgastro2017162_CR36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0884533610368710","volume":"25","author":"M Bower","year":"2010","unstructured":"Bower, M., Jones, W., Vessels, B., Scoggins, C. & Martin, R. Role of esophageal stents in the nutrition support of patients with esophageal malignancy. Nutr. Clin. Pract. 25, 244\u2013249 (2010).","journal-title":"Nutr. Clin. Pract."},{"key":"BFnrgastro2017162_CR37","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1442-2050.2008.00905.x","volume":"22","author":"AA Siddiqui","year":"2009","unstructured":"Siddiqui, A. A., Glynn, C., Loren, D. & Kowalski, T. Self-expanding plastic esophageal stents versus jejunostomy tubes for the maintenance of nutrition during neoadjuvant chemoradiation therapy in patients with esophageal cancer: a retrospective study. Dis. Esophagus 22, 216\u2013222 (2009).","journal-title":"Dis. Esophagus"},{"key":"BFnrgastro2017162_CR38","first-page":"CD004310","volume":"2","author":"EG Berenstein","year":"2005","unstructured":"Berenstein, E. G. & Ortiz, Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst. Rev. 2, CD004310 (2005).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrgastro2017162_CR39","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2005.01.8010","volume":"23","author":"T Yavuzsen","year":"2005","unstructured":"Yavuzsen, T., Davis, M. P., Walsh, D., LeGrand, S. & Lagman, R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J. Clin. Oncol. 23, 8500\u20138511 (2005).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR40","doi-asserted-by":"crossref","first-page":"e0128616","DOI":"10.1371\/journal.pone.0128616","volume":"10","author":"LL Zhu","year":"2015","unstructured":"Zhu, L. L.  et al. A meta-analysis of concurrent chemoradiotherapy for advanced esophageal cancer. PLoS ONE 10, e0128616 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2017162_CR41","first-page":"CD002092","volume":"1","author":"R Wong","year":"2006","unstructured":"Wong, R. & Malthaner, R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst. Rev. 1, CD002092 (2006).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrgastro2017162_CR42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/030089161209800108","volume":"98","author":"J Han","year":"2012","unstructured":"Han, J.  et al. Clinical study of concurrent chemoradiotherapy or radiotherapy alone for esophageal cancer patients with positive lymph node metastasis. Tumori 98, 60\u201365 (2012).","journal-title":"Tumori"},{"key":"BFnrgastro2017162_CR43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/COC.0b013e3181dbbafe","volume":"34","author":"EF Courrech Staal","year":"2011","unstructured":"Courrech Staal, E. F.  et al. Chemoradiation for esophageal cancer: institutional experience with three different regimens. Am. J. Clin. Oncol. 34, 343\u2013349 (2011).","journal-title":"Am. J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR44","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/COC.0b013e3181aaca26","volume":"33","author":"BN Ruppert","year":"2010","unstructured":"Ruppert, B. N.  et al. Cisplatin\/Irinotecan versus carboplatin\/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am. J. Clin. Oncol. 33, 346\u2013352 (2010).","journal-title":"Am. J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/JTO.0b013e31802bff75","volume":"2","author":"H Wang","year":"2007","unstructured":"Wang, H.  et al. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J. Thorac. Oncol. 2, 153\u2013157 (2007).","journal-title":"J. Thorac. Oncol."},{"key":"BFnrgastro2017162_CR46","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/annonc\/mdt589","volume":"25","author":"J Honing","year":"2014","unstructured":"Honing, J.  et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann. Oncol. 25, 638\u2013643 (2014).","journal-title":"Ann. Oncol."},{"key":"BFnrgastro2017162_CR47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1442-2050.2009.01003.x","volume":"23","author":"QQ Li","year":"2010","unstructured":"Li, Q. Q.  et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis. Esophagus 23, 253\u2013259 (2010).","journal-title":"Dis. Esophagus"},{"key":"BFnrgastro2017162_CR48","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1470-2045(14)70028-2","volume":"15","author":"T Conroy","year":"2014","unstructured":"Conroy, T.  et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5\/ACCORD17): final results of a randomised, phase 2\/3 trial. Lancet Oncol. 15, 305\u2013314 (2014).","journal-title":"Lancet Oncol."},{"issue":"Suppl. 3","key":"BFnrgastro2017162_CR49","doi-asserted-by":"crossref","first-page":"LBA6","DOI":"10.1200\/jco.2014.32.3_suppl.lba6","volume":"32","author":"M Suntharalingam","year":"2014","unstructured":"Suntharalingam, M.  et al. The initial report of RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery [abstract]. J. Clin. Oncol. 32 (Suppl. 3), LBA6 (2014).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR50","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2002.20.5.1167","volume":"20","author":"BD Minsky","year":"2002","unstructured":"Minsky, B. D.  et al. INT 0123 (Radiation Therapy Oncology Group 94\u201305) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J. Clin. Oncol. 20, 1167\u20131174 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR51","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1586\/14737140.2015.1074041","volume":"15","author":"T Song","year":"2015","unstructured":"Song, T., Liang, X., Fang, M. & Wu, S. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis. Expert Rev. Anticancer Ther. 15, 1157\u20131169 (2015).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"BFnrgastro2017162_CR52","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ijrobp.2012.02.015","volume":"84","author":"SH Lin","year":"2012","unstructured":"Lin, S. H.  et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy versus intensity-modulated radiotherapy for esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 84, 1078\u20131085 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrgastro2017162_CR53","first-page":"CD004064","volume":"3","author":"AD Wagner","year":"2010","unstructured":"Wagner, A. D.  et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev. 3, CD004064 (2010).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl. 5","key":"BFnrgastro2017162_CR54","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","volume":"27","author":"F Lordick","year":"2016","unstructured":"Lordick, F.  et al. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27 (Suppl. 5), v50\u2013v57 (2016).","journal-title":"Ann. Oncol."},{"key":"BFnrgastro2017162_CR55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/annonc\/mdn716","volume":"20","author":"I Chau","year":"2009","unstructured":"Chau, I.  et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma \u2014 individual patient data from 1775 patients in four randomised controlled trials. Ann. Oncol. 20, 885\u2013891 (2009).","journal-title":"Ann. Oncol."},{"key":"BFnrgastro2017162_CR56","first-page":"316","volume":"6","author":"DH Ilson","year":"2000","unstructured":"Ilson, D. H.  et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J. 6, 316\u2013323 (2000).","journal-title":"Cancer J."},{"key":"BFnrgastro2017162_CR57","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1999.17.10.3270","volume":"17","author":"DH Ilson","year":"1999","unstructured":"Ilson, D. H.  et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J. Clin. Oncol. 17, 3270\u20133275 (1999).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham, D.  et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36\u201346 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2017162_CR59","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran, S. E.  et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J. Clin. Oncol. 26, 1435\u20131442 (2008).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR60","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang, Y. K.  et al. Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann. Oncol. 20, 666\u2013673 (2009).","journal-title":"Ann. Oncol."},{"key":"BFnrgastro2017162_CR61","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdp047","volume":"20","author":"AF Okines","year":"2009","unstructured":"Okines, A. F., Norman, A. R., McCloud, P., Kang, Y. K. & Cunningham, D. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann. Oncol. 20, 1529\u20131534 (2009).","journal-title":"Ann. Oncol."},{"key":"BFnrgastro2017162_CR62","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","volume":"28","author":"JA Ajani","year":"2010","unstructured":"Ajani, J. A.  et al. Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J. Clin. Oncol. 28, 1547\u20131553 (2010).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR63","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s10120-015-0587-8","volume":"19","author":"E Ter Veer","year":"2016","unstructured":"Ter Veer, E.  et al. The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. Gastric Cancer 19, 696\u2013712 (2016).","journal-title":"Gastric Cancer"},{"key":"BFnrgastro2017162_CR64","unstructured":"[No authors listed.] A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4'-epirubicin (FPEPIR). Kyoto research group for chemotherapy of gastric cancer (KRGCGC). Anticancer Res. 12, 1983\u20131988 (1992)."},{"issue":"Suppl. 6","key":"BFnrgastro2017162_CR65","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0959-8049(01)81651-8","volume":"37","author":"TW Kim","year":"2001","unstructured":"Kim, T. W.  et al. A prospective randomized phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5-fu (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC). Eur. J. Cancer 37 (Suppl. 6), 314 (2001).","journal-title":"Eur. J. Cancer"},{"key":"BFnrgastro2017162_CR66","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1200\/JCO.2002.08.105","volume":"20","author":"P Ross","year":"2002","unstructured":"Ross, P.  et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol. 20, 1996\u20132004 (2002).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR67","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10555-015-9576-y","volume":"34","author":"NH Mohammad","year":"2015","unstructured":"Mohammad, N. H.  et al. Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. Cancer Metastasis Rev. 34, 429\u2013441 (2015).","journal-title":"Cancer Metastasis Rev."},{"key":"BFnrgastro2017162_CR68","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.2015.65.5092","volume":"34","author":"PC Enzinger","year":"2016","unstructured":"Enzinger, P. C.  et al. CALGB 80403 (alliance)\/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. J. Clin. Oncol. 34, 2736\u20132742 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR69","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem, E.  et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J. Clin. Oncol. 24, 4991\u20134997 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR70","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2006.08.3956","volume":"25","author":"JA Ajani","year":"2007","unstructured":"Ajani, J. A.  et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group. J. Clin. Oncol. 25, 3210\u20133216 (2007).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR71","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ejca.2012.09.025","volume":"49","author":"SE Al-Batran","year":"2013","unstructured":"Al-Batran, S. E.  et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). Eur. J. Cancer 49, 835\u2013842 (2013).","journal-title":"Eur. J. Cancer"},{"key":"BFnrgastro2017162_CR72","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/annonc\/mdm269","volume":"18","author":"S Lorenzen","year":"2007","unstructured":"Lorenzen, S.  et al. Split-dose docetaxel, cisplatin and leucovorin\/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann. Oncol. 18, 1673\u20131679 (2007).","journal-title":"Ann. Oncol."},{"key":"BFnrgastro2017162_CR73","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/cncr.24925","volume":"116","author":"MJ Overman","year":"2010","unstructured":"Overman, M. J.  et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 116, 1446\u20131453 (2010).","journal-title":"Cancer"},{"key":"BFnrgastro2017162_CR74","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.bjc.6605522","volume":"102","author":"NC Tebbutt","year":"2010","unstructured":"Tebbutt, N. C.  et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br. J. Cancer 102, 475\u2013481 (2010).","journal-title":"Br. J. Cancer"},{"key":"BFnrgastro2017162_CR75","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10120-015-0457-4","volume":"19","author":"J Wang","year":"2016","unstructured":"Wang, J.  et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer 19, 234\u2013244 (2016).","journal-title":"Gastric Cancer"},{"key":"BFnrgastro2017162_CR76","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang, Y. J.  et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687\u2013697 (2010).","journal-title":"Lancet"},{"key":"BFnrgastro2017162_CR77","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","volume":"14","author":"F Lordick","year":"2013","unstructured":"Lordick, F.  et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 14, 490\u2013499 (2013).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR78","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1470-2045(14)70023-3","volume":"15","author":"T Iveson","year":"2014","unstructured":"Iveson, T.  et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 15, 1007\u20131018 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR79","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/jco.2015.33.15_suppl.4000","volume":"33","author":"D Cunningham","year":"2015","unstructured":"Cunningham, D.  et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G\/GEJ) cancer: RILOMET-1 study. J. Clin. Oncol. 33, 4000 (2015).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR80","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","volume":"29","author":"A Ohtsu","year":"2011","unstructured":"Ohtsu, A.  et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 29, 3968\u20133976 (2011).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR81","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s10120-014-0351-5","volume":"18","author":"L Shen","year":"2015","unstructured":"Shen, L.  et al. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer 18, 168\u2013176 (2015).","journal-title":"Gastric Cancer"},{"key":"BFnrgastro2017162_CR82","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","volume":"24","author":"F Kamangar","year":"2006","unstructured":"Kamangar, F., Dores, G. M. & Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24, 2137\u20132150 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR83","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1002\/1097-0142(19930515)71:10<2918::AID-CNCR2820711006>3.0.CO;2-V","volume":"71","author":"E Bollschweiler","year":"1993","unstructured":"Bollschweiler, E.  et al. Is the prognosis for Japanese and German patients with gastric cancer really different? Cancer 71, 2918\u20132925 (1993).","journal-title":"Cancer"},{"key":"BFnrgastro2017162_CR84","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"47","author":"PC Thuss-Patience","year":"2011","unstructured":"Thuss-Patience, P. C.  et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer \u2014 a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur. J. Cancer 47, 2306\u20132314 (2011).","journal-title":"Eur. J. Cancer"},{"key":"BFnrgastro2017162_CR85","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","volume":"30","author":"JH Kang","year":"2012","unstructured":"Kang, J. H.  et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J. Clin. Oncol. 30, 1513\u20131518 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 4","key":"BFnrgastro2017162_CR86","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2016.34.4_suppl.5","volume":"34","author":"YK Kang","year":"2016","unstructured":"Kang, Y.K.  et al. A randomized, open-label, multicenter, adaptive phase 2\/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma (LA\/MGC\/GEJC). J. Clin. Oncol. 34 (Suppl. 4), 5 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 4","key":"BFnrgastro2017162_CR87","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jco.2016.34.4_suppl.7","volume":"34","author":"T Doi","year":"2016","unstructured":"Doi, T.  et al. Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475). J. Clin. Oncol. 34 (Suppl. 4), 7 (2016).","journal-title":"J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR88","doi-asserted-by":"publisher","unstructured":"Kojima, T.  et al. Phase II study of nivolumab (ONO-4538\/BMS-936558) in patients with esophageal cancer: preliminary report of overall survival. J. Clin. Oncol. \n                    http:\/\/dx.doi.org\/10.1200\/jco.2016.34.4_suppl.tps175\n                    \n                   (2016).","DOI":"10.1200\/jco.2016.34.4_suppl.tps175"},{"key":"BFnrgastro2017162_CR89","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(16)30094-8","volume":"17","author":"EC Smyth","year":"2016","unstructured":"Smyth, E. C. & Cunningham, D. Encouraging results for PD-1 inhibition in gastric cancer. Lancet Oncol. 17, 682\u2013683 (2016).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR90","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network  et al. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169\u2013175 (2017).","DOI":"10.1038\/nature20805"},{"key":"BFnrgastro2017162_CR91","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/bmj.1.6056.266","volume":"1","author":"M Atkinson","year":"1977","unstructured":"Atkinson, M. & Ferguson, R. Fibreoptic endoscopic palliative intubation of inoperable oesophagogastric neoplasms. Br. Med. J. 1, 266\u2013267 (1977).","journal-title":"Br. Med. J."},{"key":"BFnrgastro2017162_CR92","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJM199310283291803","volume":"329","author":"K Knyrim","year":"1993","unstructured":"Knyrim, K., Wagner, H. J., Bethge, N., Keymling, M. & Vakil, N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N. Engl. J. Med. 329, 1302\u20131307 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2017162_CR93","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0016-5107(96)70290-0","volume":"43","author":"GD De Palma","year":"1996","unstructured":"De Palma, G. D.  et al. Plastic prosthesis versus expandable metal stents for palliation of inoperable esophageal thoracic carcinoma: a controlled prospective study. Gastrointest. Endosc. 43, 478\u2013482 (1996).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR94","first-page":"653","volume":"10","author":"CD Roseveare","year":"1998","unstructured":"Roseveare, C. D.  et al. Metal stents improve dysphagia, nutrition and survival in malignant oesophageal stenosis: a randomized controlled trial comparing modified Gianturco Z-stents with plastic Atkinson tubes. Eur. J. Gastroenterol. Hepatol. 10, 653\u2013657 (1998).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"BFnrgastro2017162_CR95","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0016-5107(98)70342-6","volume":"47","author":"PD Siersema","year":"1998","unstructured":"Siersema, P. D., Hop, W. C., Dees, J., Tilanus, H. W. & van Blankenstein, M. Coated self-expanding metal stents versus latex prostheses for esophagogastric cancer with special reference to prior radiation and chemotherapy: a controlled, prospective study. Gastrointest. Endosc. 47, 113\u2013120 (1998).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR96","first-page":"640","volume":"89","author":"C Sanyika","year":"1999","unstructured":"Sanyika, C., Corr, P. & Haffejee, A. Palliative treatment of oesophageal carcinoma \u2014 efficacy of plastic versus self-expandable stents. S. Afr. Med. J. 89, 640\u2013643 (1999).","journal-title":"S. Afr. Med. J."},{"key":"BFnrgastro2017162_CR97","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1046\/j.1365-2168.2002.02152.x","volume":"89","author":"CA Donnell","year":"2002","unstructured":"O' Donnell, C. A.  et al. Randomized clinical trial comparing self-expanding metallic stents with plastic endoprostheses in the palliation of oesophageal cancer. Br. J. Surg. 89, 985\u2013992 (2002).","journal-title":"Br. J. Surg."},{"key":"BFnrgastro2017162_CR98","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/ajg.2009.155","volume":"104","author":"J Shenfine","year":"2009","unstructured":"Shenfine, J., McNamee, P., Steen, N., Bond, J. & Griffin, S. M. A randomized controlled clinical trial of palliative therapies for patients with inoperable esophageal cancer. Am. J. Gastroenterol. 104, 1674\u20131685 (2009).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2017162_CR99","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1007\/s10620-010-1250-1","volume":"55","author":"G Sgourakis","year":"2010","unstructured":"Sgourakis, G.  et al. The use of self-expanding stents in esophageal and gastroesophageal junction cancer palliation: a meta-analysis and meta-regression analysis of outcomes. Dig. Dis. Sci. 55, 3018\u20133030 (2010).","journal-title":"Dig. Dis. Sci."},{"key":"BFnrgastro2017162_CR100","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.giec.2011.04.006","volume":"21","author":"FP Vleggaar","year":"2011","unstructured":"Vleggaar, F. P. & Siersema, P. D. Expandable stents for malignant esophageal disease. Gastrointest. Endosc. Clin. N. Am. 21, 377\u2013388 (2011).","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"BFnrgastro2017162_CR101","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1148\/radiology.202.2.9015054","volume":"202","author":"A Adam","year":"1997","unstructured":"Adam, A.  et al. Palliation of inoperable esophageal carcinoma: a prospective randomized trial of laser therapy and stent placement. Radiology 202, 344\u2013348 (1997).","journal-title":"Radiology"},{"key":"BFnrgastro2017162_CR102","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/j.1572-0241.2001.03923.x","volume":"96","author":"N Vakil","year":"2001","unstructured":"Vakil, N.  et al. A prospective, randomized, controlled trial of covered expandable metal stents in the palliation of malignant esophageal obstruction at the gastroesophageal junction. Am. J. Gastroenterol. 96, 1791\u20131796 (2001).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2017162_CR103","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.gie.2009.05.032","volume":"70","author":"MJ Uitdehaag","year":"2009","unstructured":"Uitdehaag, M. J.  et al. A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study. Gastrointest. Endosc. 70, 1082\u20131089 (2009).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR104","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0016-5107(04)02047-4","volume":"60","author":"MY Homs","year":"2004","unstructured":"Homs, M. Y.  et al. Esophageal stents with antireflux valve for tumors of the distal esophagus and gastric cardia: a randomized trial. Gastrointest. Endosc. 60, 695\u2013702 (2004).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR105","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1440-1746.2008.05396.x","volume":"23","author":"T Sabharwal","year":"2008","unstructured":"Sabharwal, T.  et al. Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction. J. Gastroenterol. Hepatol. 23, 723\u2013728 (2008).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFnrgastro2017162_CR106","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1111\/j.1572-0241.2007.01565.x","volume":"102","author":"M Conio","year":"2007","unstructured":"Conio, M.  et al. A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. Am. J. Gastroenterol. 102, 2667\u20132677 (2007).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2017162_CR107","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1572-0241.2007.01542.x","volume":"103","author":"EM Verschuur","year":"2008","unstructured":"Verschuur, E. M., Repici, A., Kuipers, E. J., Steyerberg, E. W. & Siersema, P. D. New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am. J. Gastroenterol. 103, 304\u2013312 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2017162_CR108","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0140-6736(04)17272-3","volume":"364","author":"MY Homs","year":"2004","unstructured":"Homs, M. Y.  et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 364, 1497\u20131504 (2004).","journal-title":"Lancet"},{"key":"BFnrgastro2017162_CR109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1067\/mge.2001.116879","volume":"54","author":"PD Siersema","year":"2001","unstructured":"Siersema, P. D.  et al. A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: a prospective, randomized study. Gastrointest. Endosc. 54, 145\u2013153 (2001).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR110","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.gie.2012.02.050","volume":"76","author":"NC van Heel","year":"2012","unstructured":"van Heel, N. C.  et al. Comparison of 2 expandable stents for malignant esophageal disease: a randomized controlled trial. Gastrointest. Endosc. 76, 52\u201358 (2012).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR111","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/00365520903443860","volume":"45","author":"J Blomberg","year":"2010","unstructured":"Blomberg, J.  et al. Antireflux stent versus conventional stent in the palliation of distal esophageal cancer. A randomized, multicenter clinical trial. Scand. J. Gastroenterol. 45, 208\u2013216 (2010).","journal-title":"Scand. J. Gastroenterol."},{"key":"BFnrgastro2017162_CR112","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00464-006-0088-2","volume":"20","author":"U Wenger","year":"2006","unstructured":"Wenger, U., Johnsson, E., Arnelo, U., Lundell, L. & Lagergren, J. An antireflux stent versus conventional stents for palliation of distal esophageal or cardia cancer: a randomized clinical study. Surg. Endosc. 20, 1675\u20131680 (2006).","journal-title":"Surg. Endosc."},{"key":"BFnrgastro2017162_CR113","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1442-2050.2007.00696.x","volume":"20","author":"C Power","year":"2007","unstructured":"Power, C.  et al. Superiority of anti-reflux stent compared with conventional stents in the palliative management of patients with cancer of the lower esophagus and esophago-gastric junction: results of a randomized clinical trial. Dis. Esophagus 20, 466\u2013470 (2007).","journal-title":"Dis. Esophagus"},{"key":"BFnrgastro2017162_CR114","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/gut.52.7.922","volume":"52","author":"T Sabharwal","year":"2003","unstructured":"Sabharwal, T.  et al. A randomised prospective comparison of the flamingo wallstent and Ultraflex stent for palliation of dysphagia associated with lower third oesophageal carcinoma. Gut 52, 922\u2013926 (2003).","journal-title":"Gut"},{"key":"BFnrgastro2017162_CR115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1055\/s-2005-861113","volume":"37","author":"CS Shim","year":"2005","unstructured":"Shim, C. S.  et al. Management of malignant stricture of the esophagogastric junction with a newly designed self-expanding metal stent with an antireflux mechanism. Endoscopy 37, 335\u2013339 (2005).","journal-title":"Endoscopy"},{"key":"BFnrgastro2017162_CR116","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1148\/radiol.2472070999","volume":"247","author":"JH Guo","year":"2008","unstructured":"Guo, J. H.  et al. Self-expandable esophageal stent loaded with 125I seeds: initial experience in patients with advanced esophageal cancer. Radiology 247, 574\u2013581 (2008).","journal-title":"Radiology"},{"key":"BFnrgastro2017162_CR117","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(14)70131-7","volume":"15","author":"HD Zhu","year":"2014","unstructured":"Zhu, H. D.  et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomised phase 3 trial. Lancet Oncol. 15, 612\u2013619 (2014).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR118","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3892\/ol.2013.1466","volume":"6","author":"Z Dai","year":"2013","unstructured":"Dai, Z.  et al. Clinical application of iodine-eluting stent in patients with advanced esophageal cancer. Oncol. Lett. 6, 713\u2013718 (2013).","journal-title":"Oncol. Lett."},{"key":"BFnrgastro2017162_CR119","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1052-3359(03)00030-9","volume":"13","author":"MF Reed","year":"2003","unstructured":"Reed, M. F. & Mathisen, D. J. Tracheoesophageal fistula. Chest Surg. Clin. N. Am. 13, 271\u2013289 (2003).","journal-title":"Chest Surg. Clin. N. Am."},{"key":"BFnrgastro2017162_CR120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.gie.2006.04.040","volume":"65","author":"WA Ross","year":"2007","unstructured":"Ross, W. A.  et al. Evolving role of self-expanding metal stents in the treatment of malignant dysphagia and fistulas. Gastrointest. Endosc. 65, 70\u201376 (2007).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR121","first-page":"532","volume":"93","author":"A May","year":"1998","unstructured":"May, A. & Ell, C. Palliative treatment of malignant esophagorespiratory fistulas with Gianturco-Z stents. A prospective clinical trial and review of the literature on covered metal stents. Am. J. Gastroenterol. 93, 532\u2013535 (1998).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2017162_CR122","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1148\/radiol.2321030733","volume":"232","author":"JH Shin","year":"2004","unstructured":"Shin, J. H.  et al. Esophagorespiratory fistula: long-term results of palliative treatment with covered expandable metallic stents in 61 patients. Radiology 232, 252\u2013259 (2004).","journal-title":"Radiology"},{"key":"BFnrgastro2017162_CR123","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5114\/jcb.2014.43780","volume":"6","author":"S Lettmaier","year":"2014","unstructured":"Lettmaier, S. & Strnad, V. Intraluminal brachytherapy in oesophageal cancer: defining its role and introducing the technique. J. Contemp. Brachytherapy 6, 236\u2013241 (2014).","journal-title":"J. Contemp. Brachytherapy"},{"key":"BFnrgastro2017162_CR124","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1442-2050.2005.00467.x","volume":"18","author":"H Bergquist","year":"2005","unstructured":"Bergquist, H.  et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis. Esophagus 18, 131\u2013139 (2005).","journal-title":"Dis. Esophagus"},{"key":"BFnrgastro2017162_CR125","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/1745-6215-15-402","volume":"15","author":"D Adamson","year":"2014","unstructured":"Adamson, D.  et al. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: radiotherapy after oesophageal cancer stenting): study protocol for a randomized controlled trial. Trials 15, 402 (2014).","journal-title":"Trials"},{"key":"BFnrgastro2017162_CR126","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0360-3016(03)00256-6","volume":"56","author":"M Suntharalingam","year":"2003","unstructured":"Suntharalingam, M.  et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996\u20131999 patterns of care study. Int. J. Radiat. Oncol. Biol. Phys. 56, 981\u2013987 (2003).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrgastro2017162_CR127","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0360-3016(97)00710-4","volume":"40","author":"RK Sur","year":"1998","unstructured":"Sur, R. K., Donde, B., Levin, V. C. & Mannell, A. Fractionated high dose rate intraluminal brachytherapy in palliation of advanced esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys. 40, 447\u2013453 (1998).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrgastro2017162_CR128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0360-3016(02)02702-5","volume":"53","author":"RK Sur","year":"2002","unstructured":"Sur, R. K.  et al. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma \u2014 an International Atomic Energy Agency study. Int. J. Radiat. Oncol. Biol. Phys. 53, 127\u2013133 (2002).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrgastro2017162_CR129","first-page":"CD005048","volume":"10","author":"Y Dai","year":"2014","unstructured":"Dai, Y.  et al. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst. Rev. 10, CD005048 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrgastro2017162_CR130","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1067\/mge.2001.118947","volume":"54","author":"HJ Dallal","year":"2001","unstructured":"Dallal, H. J.  et al. A randomized trial of thermal ablative therapy versus expandable metal stents in the palliative treatment of patients with esophageal carcinoma. Gastrointest. Endosc. 54, 549\u2013557 (2001).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR131","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/gut.50.2.224","volume":"50","author":"GM Spencer","year":"2002","unstructured":"Spencer, G. M.  et al. Laser augmented by brachytherapy versus laser alone in the palliation of adenocarcinoma of the oesophagus and cardia: a randomised study. Gut 50, 224\u2013227 (2002).","journal-title":"Gut"},{"key":"BFnrgastro2017162_CR132","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/ajg.2011.178","volume":"106","author":"M Rupinski","year":"2011","unstructured":"Rupinski, M.  et al. Randomized comparison of three palliative regimens including brachytherapy, photodynamic therapy, and APC in patients with malignant dysphagia (CONSORT 1a) (revised II). Am. J. Gastroenterol. 106, 1612\u20131620 (2011).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2017162_CR133","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0016-5107(91)70775-X","volume":"37","author":"R Sander","year":"1991","unstructured":"Sander, R., Hagenmueller, F., Sander, C., Riess, G. & Classen, M. Laser versus laser plus afterloading with iridium-192 in the palliative treatment of malignant stenosis of the esophagus: a prospective, randomized, and controlled study. Gastrointest. Endosc. 37, 433\u2013440 (1991).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR134","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gut.40.3.362","volume":"40","author":"IR Sargeant","year":"1997","unstructured":"Sargeant, I. R.  et al. Radiotherapy enhances laser palliation of malignant dysphagia: a randomised study. Gut 40, 362\u2013369 (1997).","journal-title":"Gut"},{"key":"BFnrgastro2017162_CR135","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.radonc.2010.09.001","volume":"97","author":"E Rosenblatt","year":"2010","unstructured":"Rosenblatt, E.  et al. Adding external beam to intra-luminal brachytherapy improves palliation in obstructive squamous cell oesophageal cancer: a prospective multi-centre randomized trial of the International Atomic Energy Agency. Radiother. Oncol. 97, 488\u2013494 (2010).","journal-title":"Radiother. Oncol."},{"key":"BFnrgastro2017162_CR136","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.brachy.2004.09.004","volume":"3","author":"R Sur","year":"2004","unstructured":"Sur, R.  et al. Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. Brachytherapy 3, 191\u2013195 (2004).","journal-title":"Brachytherapy"},{"key":"BFnrgastro2017162_CR137","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.radonc.2013.04.008","volume":"107","author":"CD Amdal","year":"2013","unstructured":"Amdal, C. D., Jacobsen, A. B., Sandstad, B., Warloe, T. & Bjordal, K. Palliative brachytherapy with or without primary stent placement in patients with oesophageal cancer, a randomised phase III trial. Radiother. Oncol. 107, 428\u2013433 (2013).","journal-title":"Radiother. Oncol."},{"key":"BFnrgastro2017162_CR138","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12029-010-9206-4","volume":"43","author":"A Javed","year":"2012","unstructured":"Javed, A.  et al. Palliative stenting with or without radiotherapy for inoperable esophageal carcinoma: a randomized trial. J. Gastrointest. Cancer. 43, 63\u201369 (2012).","journal-title":"J. Gastrointest. Cancer."},{"key":"BFnrgastro2017162_CR139","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0360-3016(01)02813-9","volume":"53","author":"Y Nishimura","year":"2002","unstructured":"Nishimura, Y.  et al. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int. J. Radiat. Oncol. Biol. Phys. 53, 134\u2013139 (2002).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrgastro2017162_CR140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s10147-011-0254-y","volume":"17","author":"Y Nishimura","year":"2012","unstructured":"Nishimura, Y.  et al. Clinical practice and outcome of radiotherapy for esophageal cancer between 1999 and 2003: the Japanese radiation oncology study group (JROSG) survey. Int. J. Clin. Oncol. 17, 48\u201354 (2012).","journal-title":"Int. J. Clin. Oncol."},{"key":"BFnrgastro2017162_CR141","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1007\/s00268-013-2074-x","volume":"37","author":"H Shimoji","year":"2013","unstructured":"Shimoji, H., Karimata, H., Nagahama, M. & Nishimaki, T. Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J. Surg. 37, 2180\u20132188 (2013).","journal-title":"World J. Surg."},{"key":"BFnrgastro2017162_CR142","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1245\/s10434-013-2885-x","volume":"20","author":"JM Pimiento","year":"2013","unstructured":"Pimiento, J. M.  et al. Outcomes associated with surgery for T4 esophageal cancer. Ann. Surg. Oncol. 20, 2706\u20132712 (2013).","journal-title":"Ann. Surg. Oncol."},{"key":"BFnrgastro2017162_CR143","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen, P.  et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074\u20132084 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2017162_CR144","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist, K. M.  et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12, 681\u2013692 (2011).","journal-title":"Lancet Oncol."},{"key":"BFnrgastro2017162_CR145","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5761\/atcs.ra.11.01676","volume":"17","author":"T Makino","year":"2011","unstructured":"Makino, T. & Doki, Y. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy versus chemo-radiotherapy followed by surgery. Ann. Thorac. Cardiovasc. Surg. 17, 221\u2013228 (2011).","journal-title":"Ann. Thorac. Cardiovasc. Surg."},{"key":"BFnrgastro2017162_CR146","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00595-014-0980-7","volume":"45","author":"H Karimata","year":"2015","unstructured":"Karimata, H., Shimoji, H. & Nishimaki, T. Clinicopathological factors predicting R0 resection and long-term survival after esophagectomy in patients with T4 esophageal cancer undergoing induction chemotherapy or chemoradiotherapy. Surg. Today 45, 479\u2013486 (2015).","journal-title":"Surg. Today"},{"key":"BFnrgastro2017162_CR147","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1442-2050.2003.00304.x","volume":"16","author":"T Noguchi","year":"2003","unstructured":"Noguchi, T.  et al. Resection surgery with neoadjuvant chemoradiotherapy improves outcomes of patients with T4 esophageal carcinoma. Dis. Esophagus 16, 94\u201398 (2003).","journal-title":"Dis. Esophagus"},{"key":"BFnrgastro2017162_CR148","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2967\/jnumed.115.163766","volume":"57","author":"PS van Rossum","year":"2016","unstructured":"van Rossum, P. S.  et al. The incremental value of subjective and quantitative assessment of 18F-FDG PET for the prediction of pathologic complete response to preoperative chemoradiotherapy in esophageal cancer. J. Nucl. Med. 57, 691\u2013700 (2016).","journal-title":"J. Nucl. Med."},{"key":"BFnrgastro2017162_CR149","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.gie.2015.11.026","volume":"83","author":"PS van Rossum","year":"2016","unstructured":"van Rossum, P. S.  et al. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis. Gastrointest. Endosc. 83, 866\u2013879 (2016).","journal-title":"Gastrointest. Endosc."},{"key":"BFnrgastro2017162_CR150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.crad.2014.07.017","volume":"70","author":"PS van Rossum","year":"2015","unstructured":"van Rossum, P. S.  et al. Imaging of oesophageal cancer with FDG-PET\/CT and MRI. Clin. Radiol. 70, 81\u201395 (2015).","journal-title":"Clin. Radiol."},{"key":"BFnrgastro2017162_CR151","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.radonc.2015.04.027","volume":"115","author":"PS van Rossum","year":"2015","unstructured":"van Rossum, P. S.  et al. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. Radiother. Oncol. 115, 163\u2013170 (2015).","journal-title":"Radiother. Oncol."},{"key":"BFnrgastro2017162_CR152","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00330-013-2773-6","volume":"23","author":"PS van Rossum","year":"2013","unstructured":"van Rossum, P. S.  et al. Imaging strategies in the management of oesophageal cancer: what's the role of MRI? Eur. Radiol. 23, 1753\u20131765 (2013).","journal-title":"Eur. Radiol."},{"key":"BFnrgastro2017162_CR153","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum, R. R. & Hellman, S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8, 378\u2013382 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"BFnrgastro2017162_CR154","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","volume":"83","author":"MT Milano","year":"2012","unstructured":"Milano, M. T., Katz, A. W., Zhang, H. & Okunieff, P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int. J. Radiat. Oncol. Biol. Phys. 83, 878\u2013886 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"BFnrgastro2017162_CR155","first-page":"CD006039","volume":"2","author":"A Al-Asfoor","year":"2008","unstructured":"Al-Asfoor, A., Fedorowicz, Z. & Lodge, M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst. Rev. 2, CD006039 (2008).","journal-title":"Cochrane Database Syst. Rev."},{"key":"BFnrgastro2017162_CR156","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.seminoncol.2007.03.004","volume":"34","author":"DI Sternberg","year":"2007","unstructured":"Sternberg, D. I. & Sonett, J. R. Surgical therapy of lung metastases. Semin. Oncol. 34, 186\u2013196 (2007).","journal-title":"Semin. Oncol."},{"key":"BFnrgastro2017162_CR157","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3322\/caac.20013","volume":"59","author":"RD Timmerman","year":"2009","unstructured":"Timmerman, R. D.  et al. Local surgical, ablative, and radiation treatment of metastases. CA Cancer. J. Clin. 59, 145\u2013170 (2009).","journal-title":"CA Cancer. J. Clin."},{"key":"BFnrgastro2017162_CR158","doi-asserted-by":"crossref","first-page":"e0120569","DOI":"10.1371\/journal.pone.0120569","volume":"10","author":"G Martel","year":"2015","unstructured":"Martel, G.  et al. Liver resection for non-colorectal, non-carcinoid, non-sarcoma metastases: a multicenter study. PLoS ONE 10, e0120569 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2017162_CR159","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.3748\/wjg.v21.i14.4111","volume":"21","author":"JR Huddy","year":"2015","unstructured":"Huddy, J. R., Ni, M. Z., Markar, S. R. & Hanna, G. B. Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions. World J. Gastroenterol. 21, 4111\u20134120 (2015).","journal-title":"World J. Gastroenterol."},{"key":"BFnrgastro2017162_CR160","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/cncr.29134","volume":"121","author":"EK Bartlett","year":"2015","unstructured":"Bartlett, E. K.  et al. The rise in metastasectomy across cancer types over the past decade. Cancer 121, 747\u2013757 (2015).","journal-title":"Cancer"},{"key":"BFnrgastro2017162_CR161","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1440-1746.2008.05674.x","volume":"24","author":"ES Kim","year":"2009","unstructured":"Kim, E. S.  et al. Comparison of double-layered and covered Niti-S stents for palliation of malignant dysphagia. J. Gastroenterol. Hepatol. 24, 114\u2013119 (2009).","journal-title":"J. Gastroenterol. Hepatol."}],"container-title":["Nature Reviews Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2017.162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2017.162","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrgastro.2017.162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2017.162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:57:52Z","timestamp":1684468672000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2017.162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,13]]},"references-count":161,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["BFnrgastro2017162"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2017.162","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,13]]},"assertion":[{"value":"13 December 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.P.V. has acted as a consultant for Boston Scientific. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}